EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes
The EMA has given a green light to new diabetes medicines, including LixiLan and a new biosimilar version of insulin glargine, as well as two biosimilar versions of teriparatide for osteoporosis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Diabetes | Endocrinology | Forteo | Health | Insulin | Lantus | Orthopaedics | Osteoporosis